Table 2 Independent review committee-assessed efficacy outcomes

From: Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study

Efficacy variable

N = 70

Objective response, n (%)

 

 Complete

44 (62.9)

 Partial

17 (24.3)

 No responsea

9 (12.8)

 Overall (%)

87.1

 95% CI for overall response rate

(77.0, 93.9)

 P-valueb

<0.0001

Time to responsec, weeks

 

 Median (range)

12.0 (8.9–42.1)

DORc, months

 

 Mediand (range)

NE (0.0+ to 10.3+)

 95% CI

(NE, NE)

 Event-free ratesc at 6 months (%)

84.1

 95% CI

(70.3, 91.8)

Progression-free survival, months

 

 Mediand (range)

NE (2.6–13.1+)

 95% CI

(NE, NE)

 Event-free ratesc at 9 months (%)

74.5

 95% CI

(70.5, 89.4)

  1.  NE denotes not estimable.  + denotes censored observations
  2. aOne patient who died from complications of progressive disease before any postbaseline tumor assessments is included in this category
  3. bOne-sided p-value was based on exact test comparison of tislelizumab ORR versus reference rate (H0) of 0.35
  4. cEvent-free rates were estimated by Kaplan–Meier methodology with 95% confidence intervals estimated using Greenwood’s formula
  5. dMedians were estimated by Kaplan–Meier methodology with 95% confidence intervals estimated using the Brookmeyer and Crowley method
Back to article page